Global Blood Therapeutics

Oxbryta Increased Haemoglobin And Reduced Haemolysis in Adults and Adolescents With SCD
Clinical News

Oxbryta Increased Haemoglobin And Reduced Haemolysis in Adults and Adolescents With SCD

Global Blood Therapeutics, Inc. announced The Lancet Haematology has published the complete analysis of 72-week data from the Phase 3 HOPE Study of Oxbryta® (voxelotor) tablets in patients with sickle cell disease…
Back to top button